Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid

Carcas, Antonio J.; Abad‐Santos, Francisco; Rosendo, Jesús M de; Frías, Jesús

doi:10.1177/106002809603000208

Cited by 11 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, seven studies were performed on normotensive women (12,13,22,27,28,36,45), six studies were performed on women being treated for an arrhythmia (15, 17, 26, 33 -35), the subjects of two case studies were being treated for cerebral vasospasm (37,38), the subject of one case study was being treated for angina (30), and one study did not report the purpose of the drug treatment (32). The stage of lactation when testing was performed varied from 1 day to 12 months, the majority of subjects being in the puerperium.…”

Section: Resultsmentioning

confidence: 99%

Excretion of Antihypertensive Medication Into Human Breast Milk: A Systematic Review

Beardmore

Morris

Gallery

2002

Hypertension in Pregnancy

137

View full text Add to dashboard Cite

The available data to date indicate that ACE inhibitors, methyldopa, beta-blockers with high protein binding, and some calcium channel blockers all appear to be safe treatments of hypertension in a nursing mother. The data suggest that drugs to be avoided are beta-blockers with low protein binding. However, the available evidence is limited and further studies are needed to confirm these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Excretion of Antihypertensive Medication Into Human Breast Milk: A Systematic Review

Beardmore

Morris

Gallery

2002

Hypertension in Pregnancy

137

View full text Add to dashboard Cite

show abstract

“…9 The dose exposed to the infant was estimated at 0.008% to 0.092% of the maternal dose. It was concluded that nimodipine passes into breast milk, although at a lower percentage than other calcium channel antagonists.…”

Section: Nimodipinementioning

confidence: 99%

“…One case report involving the use of nimodipine 46 mg intravenously over 24 hours showed that the milkto-plasma AUC ratio is 0.06 to 0.15. 9 The dose exposed to the infant was estimated at 0.008% to 0.092% of the maternal dose. It was concluded that nimodipine passes into breast milk, although at a lower percentage than other calcium channel antagonists.…”

Section: Nimodipinementioning

confidence: 99%

Calcium Channel Antagonists and Lactation: An Update

Shannon

Malecha²,

2000

J Hum Lact

View full text Add to dashboard Cite

Approximately 14% of women of age 20-54 years old have hypertension. For those women who are on medication for hypertension and are pregnant, this poses potential problems. In many cases, antihypertensive agents may be continued in women with chronic hypertension if taken prior to pregnancy. This article discusses the antihypertensive class, calcium channel antagonists, with regard to their physiochemical properties and lactation.

show abstract

“…or matched placebo tablets (Baeyer, Inc., West Haven, CT) every six hours beginning 18 h prior to the testing procedure and on the test day 3 h prior to the administration of ketamine hydrochloride (Calipsol, Gedeon Rihter, Inc., Hungary) or saline infusion. This study employed this extended nimodipine pretreatment paradigm as an attempt to compensate partially for the limited central nervous system bioavailability of nimodipine (Carcas et al 1996). Ketamine was administered as a 1-min intravenous bolus of 0.25 mg/kg followed by a 1-hour intravenous infusion of 0.5 mg/kg.…”

Section: Drug Administrationmentioning

confidence: 99%

Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists

Krupitsky

2001

Neuropsychopharmacology

View full text Add to dashboard Cite

Ketamine blocks the calcium channel associated with N-methyl-D-aspartate (NMDA) glutamate receptors. It has transient behavioral effects in healthy humans that resemble aspects of schizophrenia, dissociative disorders, and ethanol intoxication. Ethanol is an antagonist of both NMDA receptors and L-type voltage-sensitive calcium channels (VSCC) and it has minimal psychotogenic activity in humans. A double-blind placebo-controlled study was conducted that evaluated whether pretreatment with the L-type VSCC antagonist, nimodipine, 90 mg D, modulated ketamine response (bolus 0.26 mg/kg, infusion of 0.65 mg/ kg/hr) (Krystal et al. 1999c). In addition, these drugs produce effects in healthy human subjects that resemble aspects of the signs and symptoms of schizophrenia or dissociative disorders (Krystal et al. 25 , NO . 6 Nimodipine-Ketamine Interactions 937 1999a). As a result, ketamine administration may provide a laboratory-based approach that may contribute to the characterization of NMDA receptor contributions to cognitive function and the development of novel pharmacotherapeutic approaches that might ameliorate the consequences of NMDA receptor dysfunction. NMDA receptor antagonists also have ethanol-like behavioral effects in animals and humans (Grant and Colombo 1993;Krystal et al. 1998b;Petrakis et al. 2001). In ethanol dependent patients, ketamine effects were deemed more similar to ethanol effects than they were to the effects of marijuana or cocaine (Krystal et al. 1998b). This observation is consistent with studies indicating that NMDA receptors are among the highest affinity targets of ethanol in the brain, where it produces dose-related uncompetitive antagonism of receptor function (Grant and Lovinger 1995;Lovinger 1997). In animals, the behavioral effects of ethanol have a complex neurobiology, reflecting the interaction of the many component dose-related actions of ethanol in the brain (Green and Grant 1998).Ethanol, relative to the uncompetitive NMDA receptor antagonists phencyclidine and ketamine, has less propensity to produce psychotic symptoms in healthy humans or recovering ethanol-dependent patients (Krystal et al. 1994a;Krystal et al. 1998b;Luby et al. 1959). The limited psychotogenic propensity of ethanol at doses typically associated with human intoxication may reflect the capacity of ethanol facilitation of GABA A receptor function to moderate its NMDA antagonist effects (Grant and Lovinger 1995). Consistent with this hypothesis, some reduction in the perceptual effects of ketamine in healthy human subjects was produced by lorazepam pretreatment (Krystal et al. 1998a). However, preclinical data suggest that the capacity of ethanol to block L-type VSCCs (Crews et al. 1996) may also protect against its psychotogenic potential. In animals, components of the behavioral and discriminative stimulus effects of NMDA antagonists are attenuated by pretreatment with L-type VSCC antagonists (Green and Grant 1999;Green-Jordan and Grant 2000;Popoli et al. 1992;Sukhotina et al. 1999).The current ...

show abstract

Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid

Abstract: Nimodipine is transferred to human milk in a lower proportion than are other calcium-channel blockers. These results suggest that treating the mother with nimodipine would entail no risk to the nursing infant.

Cited by 11 publications

References 6 publications

Excretion of Antihypertensive Medication Into Human Breast Milk: A Systematic Review

Excretion of Antihypertensive Medication Into Human Breast Milk: A Systematic Review

Calcium Channel Antagonists and Lactation: An Update

Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists

Contact Info

Product

Resources

About